Home » Taiho Announces Results of TAS-102 Phase II Trial for Metastatic Colorectal Cancer
Taiho Announces Results of TAS-102 Phase II Trial for Metastatic Colorectal Cancer
Taiho Pharmaceutical announced the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer.
News-Medical
News-Medical
Upcoming Events
-
07May
-
14May
-
30May